medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2019, Number 1

<< Back Next >>

Revista Cubana de Salud Pública 2019; 45 (1)

Consumption of selected antimicrobials at “William Soler” Pediatric Cardiocenter, 2011-2015

Castillo MD, Alfonso OI, Lambert MJM

Language: Spanish
References: 25
Page: 1-15
PDF size: 239.98 Kb.


ABSTRACT

Introduction: The irrational use of antimicrobials is a health problem. In "William Soler" Pediatric Cardiocenter there is a wide use of them; however, the behavior of the consumption of this pharmacological group in the institution is not known.
Objective: To describe the consumption of selected antimicrobials in the institution in the period 2011-2015.
Method: Descriptive, longitudinal study of the use of medicines for the consumption of 11 antimicrobials, of restricted use and high cost (cefepime, meropenem, oral and parenteral levofloxacin, linezolid, teicoplanin, vancomycin, colistin, aztreonam and amoxicillin / oral and parenteral sulbactam). The average consumption in physical units was obtained from the stowage cards of the drug store of the in-hospital pharmacy. For the calculation, the formula established by the World Health Organization was used and this is expressed in a defined daily dose/100 beds/day (DDD/100 beds/day).
Results: An increase of 7.28 DDD/100 beds/day was observed; the years 2013 and 2015 were shown as those with the highest consumption. The most consumed drugs were meropenem with an increase of 2.71 DD/100 beds/day; cefepime with an increase of 1.68 DD/100 beds/day; and linezolid with an increase of 1.15 DDD/100 beds/day. Therapy room 1 and room 1A showed the highest consumption values.
Conclusions: Antimicrobials have reduced in a crucial way the threat that infectious diseases represent, and they are also an indispensable tool in the treatment of patients in hospitals. The consumption of selected antimicrobials considered of high cost and restricted use in “William Soler” Pediatric Cardiocenter shows a tendency to increase, which shows the need to develop a program to optimize the use of antimicrobials in the institution.


REFERENCES

  1. Livermore D M. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis. 2003;36:11-23.

  2. Morales Felipe E, Villa Lorenzo A, Fernández Pola B, López MA, Mella S, Muñoz M. Evolución del consumo de antimicrobianos de uso restringido y tendencia de la susceptibilidad in vitro en el Hospital Regional de Concepción, Chile. Rev Chilena Infectol. 2012;29(5):492-8.

  3. Rodríguez-Baño J, Paño-Pardo JR, Álvarez-Rocha L, Asensio A, Calbo E, Cercenado E, et al. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH. Enferm Infecc Microbiol Clin. 2012;30(1):1-23.

  4. Bidone N, Giglio N, Bakir J, Sheehan MG, Arias López MP, Rosin M, et al. Prescripción y uso de antibióticos en una unidad de cuidados intensivos pediátricos de la Ciudad de Buenos Aires. Arch Argent Pediatr. 2008;106 (5):409-15.

  5. Vega EM, Fontana D, Iturrieta M, Segovia L, Rodríguez G, Agüero S. Consumo de antimicrobianos en la Unidad de Terapia Intensiva del Hospital Dr. Guillermo Rawson-San Juan, Argentina. Rev Chilena Infectol. 2015;32(3):259-65.

  6. Tenover F C. Mechanisms of antimicrobial resistance in bacteria. Am J Med. 2006;119(6, Suppl 1):3-10.

  7. Hutchinson J, Patrick D, Marra F, Helen N, Bowie W, Heule L, et al. Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Therapeutic Chemical classification and Defined Daily Dose system methodology in Canada. Can J Infect Dis. 2004;15(1):29-35.

  8. World Health Organization. Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment; 2016.

  9. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2011. Stockholm: ECDC; 2014. Acceso: 02/05/2016. Disponible en: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-consumptioneurope- surveillance-2011.pdf

  10. Wirtz VJ, Mol P, Verdijk J, Stichele R, Taxis K. Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. Tropical Medicine and International Health. 2013;18(4):416-25.

  11. Furones J, Mederos A, Cordero A, Cruz MA, Aguilera F. Caracterización de los estudios de utilización de medicamentos publicados en revistas médicas cubanas, 1990-2003. Rev Cub Farm [Internet]. 2006;40(1). Acceso: 06/04/2012. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152006000100007&lng=es

  12. Pérez-Martínez L, García-Milián AJ, Alonso-Carbonell L, Rodríguez-Rojas S. Consumo de antimicrobianos de uso exclusivo hospitalario. Holguín 2008-2012. Revista Salud Quintana Roo. 2014;29(7):21-25.

  13. Cruz Barrios MA. Estudios de utilización de medicamentos. En: Furones JA, Lara C, Barbado DM, Jiménez G, Pérez J, Cruz MA, editores. Farmacoepidemiología. Uso racional de medicamentos. La Habana: Editorial Academia; 2010. p 15-27.

  14. Candel FJ, López L, García AB, Chiarella F, Picazo JJ. Actualización en Patología Infecciosa 2015. Rev Esp Quimioter. 2015;28(Suppl. 1):S1-S4

  15. Seguro ML, Lujan Alovero F, Lamberghini R. Consumo de antimicrobianos en un hospital privado: efecto de un programa para el uso racional. Rev. Bras. Farm. Hosp. Serv. Saúde São Paulo. 2013;4(2):28-34.

  16. Ávila NM, Aguilera CS, Rigo H. Evolución del consumo de antibióticos y resistencia antimicrobiana en un hospital de argentina. Rev. Bras. Farm. Hosp. Serv. Saúde São Paulo. 2014;2(5):8-13.

  17. Collado R, Losa JE, Álvaro EA, Toro P, Moreno L, Pérez M. Evaluación del consumo de antimicrobianos mediante DDD/100 estancias versus DDD/100 altas en la implantación de un Programa de Optimización del Uso de Antimicrobianos. Rev Esp Quimioter. 2015;28(6):317-321.

  18. Maortua H. Relationship between in-hospital bacterial resistance and antimicrobial use over a 13-year period. Sección Microbiología, Hospital Santiago Apóstol, Vitoria-Gasteiz, España. Enferm Infecc Microbiol Clin. 2009;27(8):441-8.

  19. Curcio D J. On behalf of the Latin American Antibiotic Use in Intensive Care Unit Group. Antibiotic prescription in intensive care units in Latin America. Rev Argent Microbiol. 2011;43(3):203-11.

  20. Uriol Castillo IE, Romero Goicochea C, Benítez Castillo S, Quispe Díaz I, Díaz Zapata B. Consumo de antimicrobianos de reserva relacionado con su indicación y prescripción en el servicio de cuidados intensivos en adultos del Hospital regional docente de Trujillo. UCV-Scientia. 2013;5(1):70-79.

  21. García Orihuela M, Ruiz Salvador AK, Alfonso Orta I, Izquierdo Delgado H, Pérez Hernández B. Uso, consumo y costo de medicamentos antimicrobianos controlados en dos servicios del Hospital Universitario “General Calixto García”. Revista Habanera de Ciencias Médicas. 2013:12(1):152-161.

  22. Grau S, Fondevilla E, Mojal S, Palomar M, Vallès J, Gudiol F, VINCat Antimicrobial Group. Antibiotic consumption at 46 VINCat hospitals from 2007 to 2009, stratified by hospital size and clinical services. Enferm Infecc Microbiol Clin. 2012;30(Suppl 3):S43- S51.

  23. Chaverri-Fernández JM, Cordero-García E, Díaz-Madriz JP, Moya-Blanco M, Vega- Brown Y. Revisión del uso de antibióticos de amplio espectro en el ambiente hospitalario privado en Costa Rica. Acta Méd Costarric. 2014;56(4):158-62.

  24. Gómez F, Tena, M. Características clínico-epidemiológicas de pacientes hospitalizados en tratamiento con antibióticos de uso restringido en un hospital de segundo nivel. Ars Pharm. 2015;56(3):161-164.

  25. Domínguez I, Rosales R, Cabello A, Bavestrello L, Labarca J. Evaluación del consumo de antimicrobianos en 15 hospitales chilenos. Resultados de un trabajo colaborativo, 2013. Rev Chilena Infectol. 2016;33(3):307-312.




2020     |     www.medigraphic.com